Pancreatic Cancer Research

ResearcherFudan University Shanghai Cancer CenterActive in the last 2 years

Qiaoming Zhi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3726-2517; OpenAlex author ID A5034329447. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2014: 1 paper · 2015: 3 papers · 2016: 4 papers · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 16

  1. Nigericin Suppresses the Wnt/β-catenin Signaling in Pancreatic Cancer Through Targeting Pre-miR-374b-PRKCA/HBP1 Axis. Co-author DOI 10.1002/mc.70008↗
  2. The Coexpression and Clinical Significance of Costimulatory Molecules B7-H1, B7-H3, and B7-H4 in Human Pancreatic Cancer [Retraction]. Co-author DOI 10.2147/ott.s379382↗
  3. Author Correction: Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA. Co-author DOI 10.1038/s41598-021-84394-4↗
  4. Nigericin Suppresses the Wnt/β-catenin Signaling in Pancreatic Cancer through Targeting pre-miR-374b-PRKCA/HBP1 Axis Co-author DOI 10.21203/rs.3.rs-52126/v1↗
  5. Inflammation Promotes Progression of Pancreatic Cancer Through WNT/β-Catenin Pathway-Dependent Manner. Co-author DOI 10.1097/mpa.0000000000001386↗
  6. High-throughput sequencing of circRNAs reveals novel insights into mechanisms of nigericin in pancreatic cancer. Last author DOI 10.1186/s12864-019-6032-3↗
  7. The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer. Co-author DOI 10.1038/s41389-018-0102-2↗
  8. Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresect… Co-author DOI 10.18632/oncotarget.21340↗
  9. Long non-coding RNA UCA1 promotes the tumorigenesis in pancreatic cancer. Last author DOI 10.1016/j.biopha.2016.08.041↗
  10. Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-κB pathway dependent repression of PP2Ac. Co-author DOI 10.1080/15384101.2015.1127468↗
  11. FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. First author DOI 10.18632/oncotarget.9975↗
  12. miRNA-101 Suppresses Epithelial-to-Mesenchymal Transition by Targeting HMGA2 in Pancreatic Cancer Cells. Co-author DOI 10.2174/1871520615666150507122142↗
  13. Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA. Co-author DOI 10.1038/srep11836↗
  14. Cantharidin and norcantharidin impair stemness of pancreatic cancer cells by repressing the β-catenin pathway and strengthen the cytotoxicity of gemcitabine an… Co-author DOI 10.3892/ijo.2015.3156↗
  15. Suppression of the Epidermal Growth Factor-like Domain 7 and Inhibition of Migration and Epithelial-Mesenchymal Transition in Human Pancreatic Cancer PANC-1 Ce… Co-author DOI 10.7314/apjcp.2015.16.9.4065↗
  16. The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer. Co-author DOI 10.2147/ott.s66809↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Min Tao · 8 shared papers, 2015–2021 · strength 0.55
  2. Zhihua Xu · 3 shared papers, 2019–2025 · strength 0.50
  3. Meng Shen · 7 shared papers, 2015–2021 · strength 0.48
  4. Fei Liu · 2 shared papers, 2019–2025 · strength 0.39
  5. Kai Chen · 5 shared papers, 2016–2021 · strength 0.39
  6. Mengyao Wu · 4 shared papers, 2015–2021 · strength 0.28
  7. Mengyao Wu · 4 shared papers, 2015–2019 · strength 0.27
  8. Wei Li · 2 shared papers, 2019–2020 · strength 0.20
  9. Wei Li · 3 shared papers, 2016–2018 · strength 0.19
  10. Shiduo Song · 2 shared papers, 2014–2022 · strength 0.19
  11. Wei Li · 2 shared papers, 2016–2021 · strength 0.18
  12. Daoming Li · 2 shared papers, 2015–2021 · strength 0.18
  13. Mengdan Xu · 2 shared papers, 2018–2019 · strength 0.15
  14. Dongming Zhu · 2 shared papers, 2014–2020 · strength 0.15
  15. Yan Chen · 1 shared paper, 2022 · strength 0.15
  16. Dechun Li · 1 shared paper, 2022 · strength 0.15
  17. Lian Lian · 2 shared papers, 2016–2017 · strength 0.11
  18. Ye Xu · 1 shared paper, 2020 · strength 0.11
  19. Min Jiang · 1 shared paper, 2020 · strength 0.11
  20. Wei Li · 2 shared papers, 2015 · strength 0.10
  21. Zhiyong Du · 1 shared paper, 2019 · strength 0.09
  22. Rui Ren · 1 shared paper, 2019 · strength 0.08
  23. Ping Chen · 1 shared paper, 2016 · strength 0.07
  24. Xiaojie Bian · 1 shared paper, 2017 · strength 0.06
  25. Yuan Hong Gao · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.